Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer

Assaf Moore,Marisa A. Kollmeier,Sean M. McBride,Nicolas Toumbacaris,Zhigang Zhang, Ahmed Lacy-Elsayegh,Alexandra Dreyfuss,Craig E. Grossman,Daniel Gorovets,Michael J. Zelefsky

European Urology Oncology（2023）

引用 0|浏览14

暂无评分

摘要

Dose-escalated stereotactic body radiation therapy resulted in superior disease control rates in comparison to lower doses, without excess late toxicity. This approach should become the standard of care for the treatment of localized prostate cancer.

查看译文

关键词

Prostate cancer,Low-risk prostate cancer,Intermediate-risk prostate cancer,Stereotactic body radiation therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要